Despite hospitals accounting for a significant 40% of the growth in national health spending between 2022 and 2024, public discourse and policy efforts continue to disproportionately focus on the soaring costs of prescription drugs. This paradox is meticulously dissected by KFF’s Larry Levitt in a recent JAMA Health Forum post, published on July 16, 2026. Levitt’s analysis highlights four primary reasons for this imbalance in attention and probes the potential avenues for more effective policy intervention to rein in escalating hospital expenditures. The stark contrast in public perception and legislative focus between these two colossal segments of the healthcare industry underscores a fundamental challenge in addressing the broader issue of healthcare affordability in the United States.
The Disparity in Public Discourse: Why Drugs Dominate the Headlines
Larry Levitt’s insights reveal that the reasons behind the heightened public and political scrutiny of drug prices are multifaceted, stemming from a combination of direct consumer experience, perceived corporate accountability, and the relative simplicity of understanding and targeting pharmaceutical costs compared to the labyrinthine world of hospital billing.
Firstly, the direct and often immediate financial impact of prescription drugs on consumers is undeniable. Patients frequently encounter drug prices at the pharmacy counter, where out-of-pocket costs, even with insurance, can be substantial. These costs are often a recurring monthly or quarterly expense, making them a constant reminder of healthcare’s financial burden. This direct exposure fosters a clear and immediate understanding of the price tag associated with a specific medication. In contrast, hospital bills are typically far more complex, often arriving weeks or months after service, heavily mediated by insurance companies, and riddled with opaque line items. The true "price" of a hospital stay is frequently obscured by negotiated rates, deductibles, co-insurance, and out-of-pocket maximums, making it difficult for the average patient to grasp the underlying costs or challenge specific charges.
Secondly, there is a pervasive "villain" narrative often associated with pharmaceutical companies. The perception that drug manufacturers prioritize massive profits over patient access, fueled by high R&D claims versus substantial marketing budgets, makes them an easier target for public anger and political condemnation. Stories of life-saving drugs costing tens or hundreds of thousands of dollars, or sudden price hikes on older medications, frequently go viral, galvanizing public outrage. Hospitals, while also for-profit entities in many cases, often benefit from a "community service" image, especially non-profit institutions. They are seen as essential local infrastructure, providing emergency care and supporting local employment, which can somewhat temper public criticism regarding their pricing practices. This narrative difference plays a crucial role in shaping media coverage and public sentiment.
Thirdly, the relative simplicity of understanding drug prices versus hospital bills contributes significantly to the disparity. A drug has a singular, identifiable price for a specific quantity, which, while varying by pharmacy or insurance plan, is generally comprehensible. This allows for easier comparisons, public shaming, and targeted policy discussions around specific drug costs. Hospital bills, conversely, are notoriously opaque. They itemize hundreds of services, procedures, and supplies, each with its own charge master price that bears little resemblance to the actual cost of care or the price paid by insurers. This complexity makes it exceedingly difficult for consumers, journalists, and even policymakers to identify specific areas of overpricing or to advocate for clear, actionable reforms. The sheer volume and intricate nature of hospital billing effectively shield much of their pricing from public scrutiny.
Finally, the perceived ease of policy intervention for drug prices has also channeled more attention towards pharmaceuticals. Legislative efforts to control drug costs, such as empowering Medicare to negotiate drug prices under the Inflation Reduction Act (IRA), offer a seemingly more direct and manageable path to reform. While challenging to implement and facing significant industry pushback, the concept of negotiating a specific drug’s price is more straightforward than attempting to regulate the myriad services and charges within a hospital system. The multifaceted nature of hospital services, from highly specialized surgeries to routine imaging, makes a comprehensive, uniform pricing control mechanism incredibly challenging to design and implement without inadvertently impacting quality or access.
The Staggering Reality of Hospital Costs
Despite the disproportionate focus on drug prices, the financial weight of hospital care on the American healthcare system is immense and growing rapidly. Levitt’s observation that hospitals accounted for 40% of national health spending growth from 2022 to 2024 underscores a critical, yet often overlooked, driver of healthcare inflation. To put this into perspective, national health expenditures (NHE) in the U.S. surpassed $4.5 trillion in 2022, with hospital care representing the largest component, accounting for approximately 31% of total spending. If hospitals are driving 40% of the growth in this massive sector, their unchecked price increases threaten to overwhelm both public and private payers.
Data from the Centers for Medicare & Medicaid Services (CMS) consistently shows hospital spending outpacing other sectors of healthcare. While specific figures for 2022-2024 are future-dated in the original article, historical trends support Levitt’s projection. For instance, in the years leading up to this period, hospital spending growth frequently exceeded that of prescription drugs. Factors contributing to this relentless escalation are numerous:
- Labor Costs: Hospitals are highly labor-intensive, and rising wages for nurses, doctors, and support staff, exacerbated by shortages, significantly contribute to operational expenses.
- Technological Advancements: The continuous adoption of cutting-edge, often expensive, medical technologies and equipment drives up costs. While these innovations improve care, their price tags are substantial.
- Consolidation: A wave of mergers and acquisitions in the hospital sector has led to larger health systems with increased market power. This reduced competition often results in higher prices for services, as dominant providers face less pressure to keep costs down.
- Administrative Burden: The complex U.S. healthcare billing and administrative system is incredibly costly. Hospitals spend vast sums on coding, billing, and negotiating with numerous insurance plans, adding to overhead.
- Uncompensated Care: Hospitals provide care to uninsured patients or those unable to pay, leading to "uncompensated care" which is often shifted to insured patients through higher prices.
A KFF analysis published in April 2024 highlighted that "Hospital Prices Have Risen Much Faster for Private Insurance Than Medicare Since 2019." This critical detail points to a two-tiered pricing system where privately insured patients and their employers effectively subsidize lower Medicare and Medicaid rates, bearing the brunt of hospital price increases. This phenomenon is a significant, yet often hidden, driver of rising premiums and out-of-pocket costs for millions of Americans.
The Consumer Experience: A Tale of Two Bills
The disparity in public attention also reflects the distinct ways consumers experience and grapple with drug versus hospital costs.
When a patient fills a prescription, the cost is immediately clear. While they may grumble about a $50 co-pay for a generic or a $500 bill for a specialty medication, the transaction is relatively transparent. They pay, they receive the drug, and the interaction ends. This clarity, even when painful, allows for direct comparisons and a concrete understanding of the expense.
Hospital bills, conversely, are often a source of profound confusion and distress. A patient might receive emergency care, undergo surgery, or have an extended stay, only to be inundated with multiple bills from the hospital, individual doctors (anesthesiologists, surgeons, radiologists), and various labs—all arriving at different times. The explanation of benefits (EOB) from their insurer can be equally bewildering, detailing "allowed amounts," "negotiated rates," and charges that often seem arbitrary. The sheer volume of medical debt in the U.S., much of it stemming from hospital services, is a testament to this issue. Research indicates that medical debt is a leading cause of personal bankruptcy, often trapping individuals and families in a cycle of financial hardship. This opaque and overwhelming experience makes it challenging for patients to advocate for themselves or for the public to coalesce around specific policy demands for hospital price reform.
Policy Interventions and Their Limitations
The policy landscape reflects the differing levels of public and political pressure.
Drug Pricing Reforms:
The most significant recent federal intervention is the Inflation Reduction Act (IRA) of 2022. This landmark legislation empowered Medicare for the first time to negotiate prices for a select number of high-cost prescription drugs, with the negotiated prices set to take effect starting in 2026. The IRA also included provisions for inflation-based rebates, penalizing drug companies that raise prices faster than inflation, and capped out-of-pocket prescription drug costs for Medicare beneficiaries at $2,000 annually. These measures represent a direct assault on the pharmaceutical industry’s pricing autonomy and are projected to save Medicare billions. However, the implementation faces intense legal challenges from pharmaceutical companies, who argue the negotiations stifle innovation and are unconstitutional.
Beyond federal efforts, several states have also pursued their own drug pricing initiatives, including prescription drug affordability boards tasked with reviewing and setting upper payment limits for certain medications, and bulk purchasing agreements.
Hospital Price Transparency and Cost Containment:
Policy efforts targeting hospital costs have been less aggressive and, arguably, less effective. The No Surprises Act, enacted in 2022, protects patients from surprise medical bills for emergency services and certain non-emergency services provided by out-of-network providers at in-network facilities. While a crucial step, it addresses only one specific aspect of hospital billing.
The CMS price transparency rules, which went into effect in 2021, require hospitals to post their standard charges for all services, both gross charges and negotiated rates with insurers, in a machine-readable format and provide a consumer-friendly list of 300 shoppable services. However, compliance has been inconsistent, and the usability of the data remains a significant challenge. Many hospitals have either failed to comply fully or have posted data in ways that are difficult for consumers to access and understand. Even when available, the sheer volume and complexity of hospital charges make it nearly impossible for an average patient to comparison shop effectively.
Other policy avenues under discussion include:
- Site-neutral payments: Paying the same rate for the same service regardless of where it is provided (e.g., in a hospital outpatient department versus an independent physician’s office). This aims to reduce the incentive for hospitals to acquire physician practices and then charge higher facility fees.
- Antitrust enforcement: Increased scrutiny of hospital mergers and acquisitions to prevent market dominance that leads to higher prices.
- Global budgets: Some states are experimenting with global budgets for hospitals, where a hospital receives a fixed amount of money to care for a population, incentivizing cost control and population health management.
Stakeholder Perspectives and Reactions
The differing policy approaches naturally elicit varied responses from key stakeholders:
- Patient Advocates: Organizations like the American Medical Association and various consumer groups consistently call for greater transparency and accountability across the entire healthcare system. They emphasize that both high drug and hospital costs contribute to medical debt, delayed care, and worse health outcomes, urging policymakers to address both with equal vigor.
- Hospital Associations: Groups such as the American Hospital Association (AHA) defend hospital pricing, citing rising operational costs, severe workforce shortages, the provision of uncompensated care, and the need for continuous investment in advanced technology and infrastructure. They argue that price controls could jeopardize access to care, particularly for vulnerable populations and rural communities.
- Pharmaceutical Industry: Led by organizations like PhRMA, the pharmaceutical industry staunchly opposes drug price negotiation, asserting that high prices are necessary to fund costly and risky research and development for new, life-saving medications. They warn that price controls would stifle innovation and delay patient access to new therapies.
- Insurers: Health insurance companies often position themselves as key negotiators, claiming their bargaining power helps to keep costs down for consumers. However, they also face criticism for high premiums, large deductibles, and narrow networks that can limit patient choice and access. They often point fingers at providers (both hospitals and pharma) for driving up costs, while providers often blame insurers for administrative burdens and payment delays.
- Policymakers: Across the political spectrum, there is a general consensus that healthcare costs are too high. However, approaches to addressing them vary significantly. Some advocate for market-based solutions and increased competition, while others push for stronger government regulation and price controls. The complexity of the healthcare system often leads to incremental changes rather than comprehensive reforms.
The Broader Economic and Societal Implications
The continued imbalance in addressing healthcare costs has profound economic and societal implications. If hospital costs continue their rapid ascent with insufficient scrutiny, they will place an increasing strain on national and state budgets, particularly Medicare and Medicaid, which are significant payers for hospital services. This could lead to difficult choices, potentially impacting other public services or necessitating tax increases.
For employers, rising hospital costs translate into higher health insurance premiums, impacting employee compensation and business competitiveness. For individuals, unchecked hospital price growth exacerbates medical debt, reduces financial stability, and can lead to avoidance of necessary care, ultimately worsening public health outcomes. The lack of transparency and the complexity of hospital billing also erode consumer trust in the healthcare system, fostering a sense of helplessness and frustration.
Larry Levitt’s analysis serves as a critical call to action, highlighting that while addressing drug prices is vital, the silent, yet significant, escalation of hospital costs cannot be ignored. A sustainable and equitable healthcare system requires a balanced and robust policy approach that tackles both fronts with equal urgency. The future of healthcare affordability in the U.S. hinges on policymakers, industry stakeholders, and the public grappling with the full spectrum of healthcare expenditures, rather than focusing on just one part of the elephant. Ignoring the 40% growth contribution of hospitals to national health spending is a luxury the nation can ill afford.
